New molecule interferes with heat shock protein activities

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 11
Volume 18
Issue 11

Researchers had identified a small molecule that inhibits the heat shock protein HSP70. They also demonstrated in their animal experiment that the HSP inhibitor could stop tumor formation and significantly extend survival.

Researchers had identified a small molecule that inhibits the heat shock protein HSP70. They also demonstrated in their animal experiment that the HSP inhibitor could stop tumor formation and significantly extend survival.

The Philadelphia-based group showed that the inhibitor, called PES, interacted with HSP70 by blocking its stress-relieving functions. It also induces HSP70-dependent cell death by disrupting the cell’s ability to remove damaged components (Mol Cell 9:15-27, 2009).

The research was conducted by Donna George, PhD, associate professor of genetics, and Julie Leu, PhD, assistant professor of genetics, both at the University of Pennsylvania School of Medicine, in collaboration with the lab of Maureen Murphy, PhD, at Fox Chase Cancer Center.

PES seems to be specifically targeting HSP70, according to Dr. George. While studies in humans are still needed, “the exciting part is that this is a pathway and a protein target that clearly is important for cancer cells,” she said.

Recent Videos
Data from the SPOTLIGHT and GLOW trials reveal that zolbetuximab increased survival in patients with CLDN18.2-positive gastric or GEJ adenocarcinoma.
The incorporation of zolbetuximab in addition to chemotherapy has shown benefit in patients with Claudin 18.2–positive gastric cancers in clinical trials.
Michael J. Hall, MD, MS, FASCO, discusses the need to reduce barriers to care for those with Li-Fraumeni syndrome, including those who live in rural areas.
Patrick Oh, MD, highlights next steps for further research in treating patients with systemic therapy in addition to radiotherapy for early-stage NSCLC.
The ability of metformin to disrupt mitochondrial metabolism may help mitigate the risk of cancer in patients with Li-Fraumeni syndrome.
Related Content